Gregoriano Claudia, Heilmann Eva, Molitor Alexandra, Schuetz Philipp
Medical University Department of Internal Medicine, Kantonsspital Aarau, Switzerland.
Faculty of Medicine, University of Basel, Basel, Switzerland.
J Thorac Dis. 2020 Feb;12(Suppl 1):S5-S15. doi: 10.21037/jtd.2019.11.63.
Important aspects of sepsis management include early diagnosis as well as timely and specific treatment in the first few hours of triage. However, diagnosis and differentiation from non-infectious causes often cause uncertainties and potential time delays. Correct use of antibiotics still represents a major challenge, leading to increased risk for opportunistic infections, resistances to multiple antimicrobial agents and toxic side effects, which in turn increase mortality and healthcare costs. Optimized procedures for reliable diagnosis and management of antibiotic therapy has great potential to improve patient care. Herein, biomarkers have been shown to improve infection diagnosis, help in early risk stratification and provide prognostic information which helps optimizing therapeutic decisions ("antibiotic stewardship"). In this context, the use of the blood infection marker procalcitonin (PCT) has gained much attention. There is still no gold standard for the detection of sepsis and use of conventional diagnostic approaches are restricted by some limitations. Therefore, additional tests are necessary to enable early and reliable diagnosis. PCT has good discriminatory properties to differentiate between bacterial and viral inflammations with rapidly available results. Further, PCT adds to risk stratification and prognostication, which may influence appropriate use of health-care resources and therapeutic options. PCT kinetics over time also improves the monitoring of critically ill patients with sepsis and thus influences decisions regarding de-escalation of antibiotics. Most importantly, PCT helps in guiding antibiotic use in patients with respiratory infection and sepsis by limiting initiation and by shortening treatment duration. To date, PCT is the best studied biomarker regarding antibiotic stewardship. Still, further research is needed to understand optimal use of PCT, also in combination with other remerging diagnostic tests for most efficient sepsis care.
脓毒症管理的重要方面包括早期诊断以及在分诊后的最初几个小时内进行及时且针对性的治疗。然而,与非感染性病因的诊断和鉴别往往会导致不确定性和潜在的时间延迟。正确使用抗生素仍然是一项重大挑战,会导致机会性感染风险增加、对多种抗菌药物产生耐药性以及出现毒副作用,进而增加死亡率和医疗成本。优化可靠诊断和抗生素治疗管理的程序具有极大潜力来改善患者护理。在此,生物标志物已被证明可改善感染诊断、有助于早期风险分层并提供预后信息,这有助于优化治疗决策(“抗生素管理”)。在这种背景下,血液感染标志物降钙素原(PCT)的使用备受关注。脓毒症检测仍没有金标准,传统诊断方法的使用受到一些限制。因此,需要额外的检测来实现早期且可靠的诊断。PCT具有良好的鉴别特性,可快速区分细菌和病毒感染,其结果也能快速获得。此外,PCT有助于风险分层和预后评估,这可能会影响医疗资源的合理使用和治疗选择。PCT随时间的变化趋势还能改善对脓毒症重症患者的监测,从而影响抗生素降阶梯治疗的决策。最重要的是,PCT通过限制抗生素的起始使用和缩短治疗持续时间,有助于指导呼吸道感染和脓毒症患者的抗生素使用。迄今为止,PCT是在抗生素管理方面研究得最为深入的生物标志物。不过,仍需要进一步研究以了解PCT的最佳使用方法,以及如何与其他新出现的诊断检测方法联合使用,以实现最有效的脓毒症治疗。